ImageneBio Appoints CMO to Expand Phase 2b ADAPTIVE Trial to UK and Europe
ImageneBio named Dr. Ben Porter-Brown, a 20-year autoimmune drug development veteran with OX40/OX40L program leadership, as Chief Medical Officer. He will build the company’s clinical organization, drive completion of the Phase 2b ADAPTIVE atopic dermatitis trial and expand sites to the UK and Europe.
1. Appointment of Chief Medical Officer
ImageneBio appointed Dr. Ben Porter-Brown as Chief Medical Officer, charging him with building and leading its clinical organization. He brings over 20 years of clinical development expertise in autoimmune and inflammatory diseases, notably in OX40/OX40L signaling inhibition.
2. Phase 2b ADAPTIVE Trial Execution and Expansion
Dr. Porter-Brown will oversee the completion of the Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis, steering enrollment, operations and data collection. He will also expand the trial footprint by adding planned sites across the UK and Europe to accelerate patient recruitment and data readouts.
3. Inducement Award and Compensation
Subject to employment in a UK subsidiary, Dr. Porter-Brown will receive an inducement award of 137,000 shares, a mix of options and restricted stock units. The award will be granted under the ImageneBio 2025 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).